Trial Profile

A Phase 1 double-blind, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety and tolerability of single ascending and multiple doses of aficamten in healthy Japanese and Caucasian participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Aug 2024 According to a Cytokinetics media release, company initiated a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants. We expect to continue enrollment throughout 2024.
19 Jun 2024 New trial record
17 Jun 2024 According to Cytokinetics media release, first patient has been dosed in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com